Illumina, Inc. (NASDAQ:ILMN) Receives $165.95 Average Target Price from Analysts

Illumina, Inc. (NASDAQ:ILMN) has been assigned a consensus rating of “Moderate Buy” from the twenty analysts that are currently covering the stock, MarketBeat.com reports. Eight investment analysts have rated the stock with a hold recommendation, ten have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $165.95.

Several research firms have recently issued reports on ILMN. Royal Bank of Canada upped their price objective on Illumina from $252.00 to $254.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 5th. TD Cowen upped their price target on Illumina from $166.00 to $177.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. JPMorgan Chase & Co. raised their price objective on shares of Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. UBS Group upped their target price on shares of Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Finally, Barclays increased their target price on shares of Illumina from $135.00 to $145.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 5th.

Institutional Investors Weigh In On Illumina

Hedge funds have recently added to or reduced their stakes in the company. HB Wealth Management LLC boosted its stake in shares of Illumina by 22.8% in the second quarter. HB Wealth Management LLC now owns 3,044 shares of the life sciences company’s stock valued at $318,000 after buying an additional 565 shares in the last quarter. Arkadios Wealth Advisors grew its stake in shares of Illumina by 3.7% during the 2nd quarter. Arkadios Wealth Advisors now owns 9,269 shares of the life sciences company’s stock worth $968,000 after purchasing an additional 327 shares during the period. UMB Bank n.a. increased its holdings in shares of Illumina by 7.0% in the 2nd quarter. UMB Bank n.a. now owns 1,341 shares of the life sciences company’s stock valued at $140,000 after purchasing an additional 88 shares in the last quarter. Principal Financial Group Inc. lifted its stake in shares of Illumina by 181.6% in the second quarter. Principal Financial Group Inc. now owns 535,899 shares of the life sciences company’s stock valued at $55,937,000 after purchasing an additional 345,584 shares during the period. Finally, Crossmark Global Holdings Inc. boosted its holdings in Illumina by 54.7% during the second quarter. Crossmark Global Holdings Inc. now owns 8,984 shares of the life sciences company’s stock worth $937,000 after buying an additional 3,178 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Stock Up 0.2 %

Shares of NASDAQ:ILMN opened at $135.27 on Thursday. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. Illumina has a fifty-two week low of $100.08 and a fifty-two week high of $156.66. The stock has a market cap of $21.45 billion, a price-to-earnings ratio of -13.58 and a beta of 1.11. The firm’s 50 day moving average price is $142.82 and its 200 day moving average price is $130.52.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.26. The business had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The company’s revenue for the quarter was down 3.5% on a year-over-year basis. During the same period in the previous year, the company earned $0.33 EPS. As a group, equities research analysts predict that Illumina will post 4.11 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.